Neurokinin 3 receptor antagonism for menopausal hot flashes

Menopausal hot flashes are common and debilitating. Menopausal Hormone Therapy (MHT) is effective for hot flashes but has risks and side effects that limit its use. NK3 receptor antagonism has emerged as a novel therapeutic strategy, leading to the recent FDA approval of fezolinetant, a first-in-cla...

Full description

Saved in:
Bibliographic Details
Published in:Cell 2023-08, Vol.186 (16), p.3332-3332.e1
Main Authors: Comninos, Alexander N., Dhillo, Waljit S.
Format: Article
Language:English
Subjects:
Hot Flashes - drug therapy
Humans
Menopause
Receptors, Neurokinin-3 - antagonists & inhibitors
Thiadiazoles - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Menopausal hot flashes are common and debilitating. Menopausal Hormone Therapy (MHT) is effective for hot flashes but has risks and side effects that limit its use. NK3 receptor antagonism has emerged as a novel therapeutic strategy, leading to the recent FDA approval of fezolinetant, a first-in-class nonhormonal treatment for menopausal hot flashes. To view this Bench to Bedside, open or download the PDF. Menopausal hot flashes are common and debilitating. Menopausal Hormone Therapy (MHT) is effective for hot flashes but has risks and side effects that limit its use. NK3 receptor antagonism has emerged as a novel therapeutic strategy, leading to the recent FDA approval of fezolinetant, a first-in-class nonhormonal treatment for menopausal hot flashes. To view this Bench to Bedside, open or download the PDF.
ISSN:0092-8674
1097-4172
DOI:10.1016/j.cell.2023.07.011